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A B S T R A C T   
Background: We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment 
of SARS-CoV-2. 
Methods: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of 
SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) 
and oxygen saturation (SpO2) of less than 93% were enrolled. They were randomly allocated into Favipiravir (1.6 
gr loading, 1.8 gr daily) and Lopinavir/Ritonavir (800/200 mg daily) treatment regimens in addition to standard 
care. In-hospital mortality, ICU admission, intubation, time to clinical recovery, changes in daily SpO2 after 5 
min discontinuation of supplemental oxygen, and length of hospital stay were quantified and compared in the 
two groups. 
Results: 380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 
centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 
21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days [SD = 6] in the Favipiravir and 8.1 
[SD = 6.5] days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was 
similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 – 1.17) and likewise the changes in the daily SpO2 
after discontinuation of supplemental oxygen (p = 0.46) 
Conclusion: Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or in-
tubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to 
clinical recovery and length of hospital stay.   
1. Introduction 
In the SARS-CoV-2 pandemic, the search for effective antiviral 
therapy resulted in trying existing antiviral drugs used previously for the 
treatment of many RNA virus-mediated diseases such as SARS, MERS, 
AIDS, and Ebola [1–3]. 
Favipiravir (Avigan) chemically known as 6-fluoro-3-hydroxy-2-pyr-
azine carboxamide utilized in Japan for the treatment of influenza in 
2002 [4], has been used for the treatment of SARS-CoV-2. It selectively 
inhibits RNA polymerase activity of viruses by binding to RNA- 
dependent RNA polymerase (RdRp) [5–6]. It has been recognized as a 
safe and effective drug treatment for influenza and Ebola [7–8] and has 
been suggested frequently as a treatment modality for SARS-CoV-2 pa-
tients [1–2,6–7,9–12] 
We therefore explored the safety and efficacy of a treatment protocol 
containing this drug in moderate to severe cases of SARS-CoV-2 
compared to an alternative regimen containing Lopinavir/Ritonavir in 
a multicenter, randomized, open-labeled study. 
2. Methods 
2.1. Patients 
Patients with the diagnosis of SARS-CoV-2 based on either a positive 
real-time polymerase chain reaction (RT-PCR) test or typical ground 
glass appearance on chest CT scan in need of hospital admission due to a 
SpO2 reduction of 93% or less were eligible to enter this study. The age 
of the patients was between 16 and 100 years old from whom an 
informed and written consent was obtained. Exclusion criteria 
comprised a history of receiving any antiviral drug such as Ribavirin, 
Oseltamivir, and Lopinavir/Ritonavir for current illness; a history of 
chronic renal or liver failure, or gastrointestinal bleeding; being too ill 
with less than 48 h life expectancy. Also, pregnancy and lactation; 
known patient of HIV infection/AIDS; and QT interval above 500 ms in 
Electrocardiogram were excluded. 
2.2. Intervention 
We compared a treatment protocol that consisted of Favipiravir 
(made by ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.) and 
hydroxychloroquine, with Lopinavir/Ritonavir and hydroxy-
chloroquine. At the time hydroxychloroquine was regarded as the 
standard of care in Iran and skipping it in the treatment protocol was 
considered unethical. The intervention group received Favipiravir 1600 
mg stat and then 600 mg every 8 h plus hydroxychloroquine 200 mg 
twice a day for 1 week. The control group received a single dose of 
hydroxychloroquine 400 mg followed by 100 + 400 Lopinavir/Ritona-
vir twice a day for 1 week. Based on concerns regarding the effect of 
combination therapy of hydroxychloroquine and Lopinavir/Ritonavir 
on QT interval, the control group received a single dose of hydroxy-
chloroquine on admission. Later on, during the trial (31 May 2020), in 
light of emerging evidence, daily hydroxychloroquine in the Favipiravir 
group was also reduced to a single dose of 400 mg for both treatment and 
control groups. Both treatment regimens could be continued up to 10 
days if needed and physicians could use identical protocols to prescribe 
other necessary drugs especially for patients in perilous conditions. 
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2.3. Trial design 
We did a multicenter randomized open-labeled clinical trial in 20 
centers. Study groups were concurrently registered and patients were 
randomly allocated into both intervention and control groups. Recruit-
ment started on the first of April and ended on the 3rd of August 2020. 
(Details of study centers are available in the Iranian Registry of Clinical 
Trial). 
2.4. Randomization 
We used stratified block randomization with variable block size of 4 
and 6 to create the random sequence for each center, having an equal 
ratio of distribution of the subjects to both treatment and control groups. 
A 4-digit special code was allocated to every patient to preserve their 
identity, and was used to recognize the subjects on the filled CRF forms. 
Sealed envelopes were used to protect the randomization sequence. We 
used a central allocation mechanism in which participating centers 
called a central randomization unit, and registered their eligible patients 
to receive the 4-digit unique code for assigned group identification. 
2.5. Conduct and monitoring 
The trial protocol was endorsed by the research committees of the 
two main universities cooperating in this study. Ethical approval was 
received from Independent Ethics Committees of the two leading uni-
versities (References: IR.IUMS.REC.1399.065 and IR.BMSU. 
REC.1399.017). Participating centers were approached and invited 
through national professional bodies and by the chief investigator. 
Initiation and progress of the study at each participating center were 
monitored via on-site visits by monitoring teams, including remote 
central monitoring using specifically designed software intended for 
this. Discrepancies and errors were detected, recorded, and reported 
back to the clinical unit for amendments. A five-member Data and Safety 
Monitoring Board was set up to scrutinize the reported adverse events. 
2.6. Outcome definition and measurement 
The primary endpoint was the number of admissions to the intensive 
care unit. We also considered the intubation of patients. Subsidiary 
endpoints were duration in hospital, In-hospital mortality, time to 
clinical recovery, and changes in SpO2 after five minutes interval of 
supplemental discontinuation of the supplemental oxygen for 5 min. 
Length of hospital stay was defined as the number of days between 
admissions and discharge on the physician’s advice. Clinical recovery 
(as an event) was defined as the persistent return of oxygen saturation on 
ambient air to above 93%, and/or absence of supplemental oxygen 
requirement and/or medical discharge. This depended on whichever 
occurred earlier. Treatment side effects were also assessed daily. (Sup-
plemental document-Study protocol) 
2.7. Safety and efficacy population 
Patients who had been randomly allocated to the Favipiravir and 
Lopinavir/Ritonavir groups comprised our “intention to treat” (ITT) 
population. We could not gather any information from the participating 
centers for 7 patients and therefore did not include them in the modified 
ITT population. The per-protocol population was defined as those pa-
tients who had received their 7 days treatment regimens. Efficacy out-
comes were assessed in both modified ITT and per-protocol populations. 
The safety population was defined as those in the study who had 
received at least one dose of Favipiravir or Lopinavir/Ritonavir which 
corresponded to the modified ITT population. 
2.8. Data management 
A software was developed to manage data collection and transfer. 
Both the software and paper CRF forms were identical. Clinical units had 
a local client of the software and locally stored their data. Data were 
then transferred at will to the main server and stored in a central 
database as the latest version. An application was also developed to 
show all the contents of CRF forms in the central database used for 
remote monitoring. 
2.9. Sample size 
We calculated our sample size to have 80% power to detect a 
reduction from 20% to 10% in ICU admissions. 
2.10. Statistical analysis 
We used Chi-squared to compare proportions of death, ICU admis-
sion, and intubation between the two groups. Length of stay in hospital 
was compared by Man Whitney U test. Time to clinical recovery between 
the two groups was compared using Survival analysis. Cox proportional 
hazard model was used to estimate hazard ratios and their 95% confi-
dence intervals. Proportional hazard assumption was checked for each 
model using proportional hazard and Log minus log survival plots 
including formal testing. Changes (from admission) in SpO2 after 
discontinuation of the supplemental oxygen for 5 min were calculated. 
Their daily values were compared between the treatment groups using 
the Generalized Estimation Equation (GEE) method considering the time 
(days), treatment, and their interaction in the model. It was also 
examined as a binary outcome at beneath and beyond 93% saturation 
level employing the logit link function. As a sensitivity analysis, multi-
level models were built to examine the possible effects of multiple 
centers. The possible effect of reduction of hydroxychloroquine treat-
ment dose in Favipiravir group following DSMB decision on all analyses 
was checked. Stata 11 (STATA Corporation) statistical software was 
used for the analysis. 
3. Results 
3.1. Study population and baseline comparison 
Between 2/4/2020–3/8/2020, 424 eligible SARS-CoV-2 patients 
were recruited and randomly allocated to the Favipiravir (216) and 
Lopinavir/Ritonavir (208) groups in 17 centers. Four centers (44 pa-
tients) were omitted from the investigation due to inadequate moni-
toring reports and data for 7 patients could not be retrieved. The flow of 
participants is outlined in Fig. 1. The remaining 373 patients were used 
for analysis as a modified ITT population, of which 300 completed the 7- 
day therapy (per-protocol population) (Fig. 1). Results presented in this 
paper are based on the modified ITT population unless otherwise spec-
ified. Characteristics of the study participants and their baseline com-
parison in the two study groups are summarized in Table 1. Table 2 
displays the additional drugs received during the study period. Fig. 2. 
3.2. Outcomes 
3.2.1. Death and intubation 
Overall, there were 47 deaths in the modified ITT population, 26 in 
the Favipiravir group, and 21 in the Lopinavir/Ritonavir group (P =
0.49). 56 people were transferred to the intensive care unit of whom 44 
were intubated. Their corresponding figures were 31 and 26 in the 
Favipiravir, and 25 and 21 in the Lopinavir/Ritonavir groups respec-
tively. The difference between these groups was not statistically signif-
icant (see Table 3). Table 4. 
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3.2.2. Length of stay in hospital 
The median length of stay in hospital among those medically dis-
charged (on physician’s advice) in the modified ITT population was 7 
days (IQR = 4–9) in the Favipiravir, and 6 days (IQR = 4–10) in the 
Lopinavir/Ritonavir groups (Mann Whitney U test, p = 0.85) (see 
Table 3). 
3.2.3. Clinical recovery 
Median survival time to clinical recovery was 6 days (IQR = 4–10) in 
the Favipiravir group and 6 days (IQR = 4–10) in the Lopinavir/Rito-
navir group. Also, the difference in the clinical recovery experience was 
not statistically significant (Log-Rank test: χ2 = 0.38; p = 0.53) (see 
Table 3). The hazard ratio for clinical recovery in Favipiravir versus 
Lopinavir/Ritonavir group was 0.94 (95% CI: 0.75–1.17) using Cox 
proportional hazard modeling. There were no serious violations of the 
proportional hazard assumption in all models used. 
3.2.4. SpO2 change over-hospitalization 
The results from the GEE model showed that the changes in daily 
SpO2 after 5 min discontinuation of supplemental oxygen at the begin-
ning of admission in un-intubated patients had no significant difference 
between the two study groups during hospitalization (p = 0.46). SpO2 
was also assessed as a binary outcome at beneath and beyond 93% 
saturation level. SpO2 in patients receiving Favipiravir treatment 
regimen was equally likely to have a remittance beyond 93% compared 
with the Lopinavir/Ritonavir treatment group after considering SpO2 on 
admission (odds ratio = 1.00 95% CI 0.71–1.42; p = 0.997). Multilevel 
modeling had no effect the results. 
3.2.5. Adverse events 
Observed adverse drug reactions have been summarized in Table 5. 
Overall, more adverse effects were associated with Lopinavir/Ritonavir 
treatment regimen than with the Favipiravir regimen. Specifically, the 
adverse effects significantly observed in the Lopinavir/Ritonavir treat-
ment regimen were gastrointestinal, allergic, and respiratory (see 
Table 5). Reduction of hydroxychloroquine treatment dose in Favipir-
avir group following DSMB decision did not affect the results. 
3.2.6. Discussion 
In our observation, the Favipiravir therapy had no influence on ICU 
admission in comparison with Lopinavir/Ritonavir (31 admissions to 
ICU versus 25). It also did not reduce the need for intubations (27 
Fig. 1. Participants flow diagram.  
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Table 1 
Participants characteristics and baseline comparison in the modified ITT popu-






Total (N = 373) 
Age - mean (SD)* 58.6 (17.5) 56.6 (17.1) 57.6 (17.3) 
Sex (Male) - no. (%) 115 (60.5) 90 (49.2) 205 (55.0) 
BMI - mean (SD) 27.2 (4.8) 27.7 (4.5) 27.4 (4.6) 
Education - no. (%)     
Elementary 110 (57.9) 107 (58.5) 217 (58.2)  
Diploma 39 (20.5) 36 (19.7) 75 (20.1)  
Bachelor 33 (17.4) 26 (14.2) 59 (15.8)  
Master 3 (1.6) 5 (2.7) 8 (2.1)  
Doctoral and 
above 
5 (2.7) 9 (4.9) 14 (3.8) 
Comorbidities - no. (%)  
Hypertension 64 (33.7) 66 (36.1) 130 (34.9)  
Diabetes 57 (30.0) 39 (21.3) 96 (25.7)  
Chronic heart 
disease 




6 (3.2) 7 (3.8) 13 (3.5)  
Asthma 7 (3.7) 7 (3.8) 14 (3.8)  
Mild liver disease 1 (0.5) 4 (2.2) 5 (1.3)  
Kidney disease 3 (1.6) 3 (1.6) 6 (1.6)  
Rheumatologic 
disease 
2 (1.1) 4 (2.2) 6 (1.6)  
Chronic 
neurologic disease 
6 (3.2) 9 (4.9) 15 (4.0) 
Vital signs on admission - no. (%)  
Fever ◦C - mean 
(SD) 
37.2 (0.7) 37.2 (0.8) 37.2 (0.8)  
Heart rate - mean 
(SD) 
90.7 (14.5) 92.0 (14.4) 91.3 (14.4)  
Respiratory rate - 
median (IQR) 
20 (8) 22 (8) 21 (8)  
SpO2 % - median 
(IQR) 
89 (5) 89 (7) 89 (6)  
Systolic BP mmHg 
- mean (SD) 
122.8 (16.6) 124.6 (14.8) 123.7 (15.8)  
Diastolic BP 
mmHg - mean 
(SD) 
77.3 (10.1) 78.1 (9.8) 77.7 (9.9) 
Symptoms - no. (%)  
Respiratory 
distress 
35 (18.9) 40 (22.6) 75 (20.7)  
Chill 17 (9.2) 15 (8.5) 32 (8.8)  
Cough 52 (28.1) 48 (27.1) 100 (27.6)  
Dyspnea 19 (10.3) 24 (13.6) 43 (11.9)  
Chest pain 127 (68.7) 133 (75.1) 260 (71.8)  
Anorexia 47 (25.4) 47 (26.6) 94 (26.0)  
Diarrhea 131 (70.8) 123 (69.5) 254 (70.2)  
Vomiting 60 (32.4) 66 (37.3) 126 (34.8)  
Abdominal pain 42 (22.7) 58 (32.7) 100 (27.6)  
Sore throat 32 (17.3) 35 (19.8) 67 (18.5)  
Myalgia 98 (53.0) 88 (49.7) 186 (51.4)  
Arthralgia 101 (54.6) 115 (65.0) 216 (59.7)  
Fatigue 24 (13.0) 31 (17.5) 55 (15.2)  
Headache 41 (22.2) 44 (24.9) 85 (23.5) 
Lung CT scan findings – no. (%)  
Ground-glass 
pattern 
163 (85.8) 153 (83.6) 316 (84.7)  
Consolidation 29 (15.3) 37 (20.2) 66 (17.7)  
Bilateral lesions 172 (90.5) 160 (87.4) 332 (89.0)  
Multi-lobar 
lesions 
173 (91.0) 160 (87.4) 333 (89.3) 
Lab assessment – no. (median)(IQR)  




































Total (N = 373)  






















































Cr (mg/dl) 173; 1.1 
(0.9–1.3) 
165; 1 (0.9–1.2) 338; 1.1 
(0.9–1.3)  
























Ca (mg/dl) 128; 8.7 
(8.3–9.1) 
124; 9 (8.3–9.4) 252; 8.8 
(8.3–9.2)  



























* Mean age was calculated in ITT population 
Table 2 
Additional treatments used in study groups in modified ITT population.  
Additional Treatments 








Oral steroid 8 (4.4) 15 (8.5) 23 (6.4) 
Intravenous steroid 41 (22.5) 35 (19.8) 76 (21.2) 
Interferon 23 (12.6) 23 (12.9) 46 (12.8) 
Remdesivir 2 (1.1) 2 (1.1) 4 (1.1) 
Other antivirals 9 (5.0) 1 (0.6) 10 (2.8) 
Plasmapheresis 1 (0.5) 4 (2.3) 5 (1.4) 
Intravenous 
Immunoglobulin (IVIG) 
2 (1.1) 4 (2.3) 6 (1.7) 
NSAIDa 28 (15.4) 25 (14.1) 53 (14.8) 
Oral Antibiotics 76 (40.0) 62 (33.9) 138 
(37.0) 
IV Antibiotics 99 (53.5) 112 (58.1) 211 
(58.1) 
Oral Anticoagulant 15 (8.1) 18 (10.1) 33 (9.1) 
IV Anticoagulant 139 (75.1) 128 (71.9) 267 
(73.6) 
Proton Pump Inhibitors 129 (69.7) 114 (64.0) 243 (6.9) 
ACEI/ARBb 26 (14.0) 23 (12.9) 49 (13.5) 
Famotidine 16 (8.6) 21 (11.8) 37 (10.2) 
Statins 26 (14.0) 21 (11.8) 47 (13.0)  
a Nonsteroidal anti-inflammatory drugs; 
b Angiotensin-converting enzyme inhibitor/Angiotensin receptor blocker 
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intubations versus 17) or in-hospital mortality (26 deaths versus 21). 
Length of hospital stay was analogous in the two therapies, respectively 
7 and 6 days. The overall clinical recovery of patients receiving Favi-
piravir was no better than those receiving Lopinavir/Ritonavir regimen 
(log-rank test: p = 0.53). Besides, the probability of clinical recovery 
during the study period was not higher in the Favipiravir compared with 
Lopinavir/Ritonavir group (HR = 0.94; 95% CI: 0.75–1.17). Change in 
SpO2 after 5 min discontinuation of supplemental oxygen from SpO2 on 
admission also followed similar patterns in the two groups (p = 0.46). 
Ethical concerns on treatment efficacy to ensure patients receive the 
best treatment prevented us from comparing the use of Favipiravir only 
versus placebo. Hydroxychloroquine and Lopinavir/Ritonavir had been 
listed as recommended treatment options in Iranian and some foreign 
guidelines [6,12–15], hence depriving patients of these two treatment 
modalities was considered unethical at the time. Emerging works of 
literature [16–18] have raised doubts on the efficacy and safety of these 
treatments. As a result, we can reasonably claim that the design we used 
in this study should be capable of showing any potential treatment 
benefit from Favipiravir if it ever existed. Furthermore, difference in the 
duration of hydroxychloroquine treatment in early trial (up until 31st of 
May 2020) in the two regimens due to QT interval prolongation con-
cerns in those who received Lopinavir/Ritonavir [19], is unlikely to 
change our interpretation of current findings. After that date, DSMB 
decided to make the doses equal. We also could not avoid using addi-
tional treatments and supplements in patients entering our study, 
particularly when their illness worsened. Instead, we followed equal 
treatment change rules for all patients regardless of their assigned 
groups. A comparison of other treatments received by patients is 
recorded in Table 2. Generally, additional treatment modalities were 
equally used. 
Our centralized allocation system protected the randomization 
sequence and provided assurances against the introduction of bias, 
despite the open-labelled design. Patients’ national identification and 
hospital admission reference numbers together with other personal in-
formation were registered in the central randomization unit before 
allocating treatment regimens to the patients. This information was 
subsequently used in data monitoring. Stratification by center enabled 
us to exclude data gathered by centers that were regarded as sub-
standard without jeopardizing the random allocation principle. 
Patients who received the Favipiravir regimen had poor recovery 
according to some outcomes. Although this was not statistically signif-
icant, it may be an noteworthy. Inferentially, this could result from the 
compensatory treatment in patients receiving the Lopinavir/Ritonavir 
treatment regimen, given the open-labelled design. At the time this 
study was performed, some anecdotal evidence in the social media from 
clinicians suggested that Favipiravir may be the effective treatment 
against SARS-CoV-2 disease. This complicated the recruitment process 
(some patients refused to give consent) and provided additional incen-
tive for extra care by hospital staff in patients not receiving Favipiravir. 
One possible explanation for our negative findings regarding the 
efficacy of Favipiravir in SARS-CoV-2 pneumonia could be the proposed 
mechanisms for the pathogenicity of this virus. The disease usually has 
an early infection phase with mild non-specific symptoms, a pulmonary 
involvement phase with or without hypoxia, and a late phase involving a 
surge in inflammatory mediators called “cytokine storm” leading to 
ARDS which is associated with high mortality [20–21]. It seems that 
those who are hospitalized because of pneumonia and low SpO2 has 
already passed the viral replication phase, and therefore are unlikely to 
benefit from antiviral treatment [21–24]. Accordingly, some studies 
suggested early prescription of the drug even in the asymptomatic or 
ambulatory phase of the disease. [25–27]. However, a newly published 
Fig. 2. Kaplan Meier Failure plot showing time to clinical recovery by treat-
ment groups in modified ITT population. 
Table 3 
Comparison of the study outcomes in Favipiravir and Lopinavir/Ritonavir treatment regimens.  




(N = 183) 
Total (N = 373) Favipiravir(N 
= 153) 
Lopinavir/Ritonavir 
(N = 147) 
Total (N = 300) 
In-hospital mortality - no. (%) 26 (13.7) 21 (11.5) 47 (12.6) Х2 = 0.41; p = 0.52 22 (14.4) 17 (11.6) 39 (13) Х2 = 0.53; 
p = 0.47 
Intubation - no. (%) 27 (14.2) 17 (9.3) 44 (11.8) Х2 = 2.17; p = 0.14 23 (15.0) 13 (8.8) 36 (12) Х2 = 2.72; 
p = 0.1 
ICU admission - no. (%) 31 (16.3) 25 (13.7) 56 (15.0) Х2 = 0.51; p = 0.47 26 (17.0) 18 (12.2) 44 (14.7) Х2 = 1.35; 
p = 0.25 
Median length of hospital stay - 
days (IQR)a 
7 (4–9); n = 153 6 (4–10); n = 150 6 (4–10); n = 303 Mann- 
Whitney U test: p = 0.85 
6 (4–9); n = 124 6 (4–9); n = 122 6 (4–9); n = 246 
Mann-Whitney U 
test: p = 0.92 
Median survival time till clinical 
recovery - days (IQRb) 
6 (4–10); n =
185 
6 (4–10); n = 182 Log-rank Х2 = 0.38; p = 0.54 6 (4–9); n = 150 5 (3–9); n = 147 Log-rank Х2 = 0.38; 
p = 0.54  
a patients discharged against medical advice were excluded 
b Inter Quartile Range 
Table 4 
Hazard ratios and their 95% CI for clinical recovery estimated from Cox pro-
portional Hazard modelling.   











152 1.00 124 1.00 
Favipiravir 
Group 
156 0.94 (0.75–1.17) 127 0.93 (0.73–1.19)  
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open-labelled randomized trial did not find any benefit from the early 
prescription of the drug compared with the late prescription, in patients 
with mild to moderate SARS-CoV-2 [28]. 
Our patients also included many with moderate cases and the 
absence of any evidence of rapid clinical recovery in the Favipiravir 
group may suggest that the severity of the disease is independent of viral 
replication, even if the findings of reduction in viral load by Favipiravir 
treatment are true [25,29–30]. This explanation is in line with the 
existing evidence showing that these patients benefited from the sup-
pression of their exaggerated immune response by steroids [31] rather 
than by any antiviral treatment. 
Our study has the strength of exploring hard outcomes such as 
mortality, ICU admission, and intubation that are less prone to differ-
ences in definitions and interpretation. In summary, we found no clinical 
benefit from a treatment regimen based on Favipiravir in moderate to 
severe cases of SARS-CoV-2 over a treatment regimen based on Lopi-
navir/Ritonavir. 
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